Innate Pharma S.A. to Host Conference Call on 2025 Financial Results

Innate Pharma SA ( (FR:IPH) ) has provided an update.

Innate Pharma S.A. announced a conference call and webcast scheduled for September 17, 2025, to discuss its financial results and business updates for the first half of 2025. The event will feature key executives, including CEO Jonathan Dickinson, and will provide insights into the company’s progress and strategic initiatives. This announcement is significant for stakeholders as it reflects Innate Pharma’s ongoing commitment to transparency and engagement with investors, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes its proprietary ANKET® platform for multi-specific NK Cell Engagers, along with Antibody Drug Conjugates and monoclonal antibodies, to target various tumor types. Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to advance cancer treatment innovations.

Average Trading Volume: 164,200

Technical Sentiment Signal: Strong Sell

Current Market Cap: €160.9M

For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.